Hepatic Arterial Infusion (HAI) of Abraxane

Phase 1 Completed 64 enrolled M.D. Anderson Cancer Center National Comprehensive Cancer Network · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.

Timeline

Start: 2008-06
Primary completion: 2016-01
Completion: 2016-01

Publications

Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb;77(2):357-64. doi: 10.1007/s00280-015-2946-x. Epub 2015 Dec 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nab-paclitaxel	Small molecule	180 mg/m2	Other
Subject	Nab-paclitaxel	Small molecule	260 mg/m2	Other

Hepatic Arterial Infusion (HAI) of Abraxane

Summary

Timeline

Publications

Drugs

Indications